- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.12. | RedChip Companies, Inc.: Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 347 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on the RedChip... ► Artikel lesen | |
| 13.11. | Calidi BioTherapeutics GAAP EPS of -$2.21 misses by $0.53 | 1 | Seeking Alpha | ||
| 13.11. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights | 381 | GlobeNewswire (Europe) | Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform... ► Artikel lesen | |
| 13.11. | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.11. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 03.11. | Cha Biotech's Matica Bio, Calidi partner on cancer immunotherapy project | 2 | Korea Herald | ||
| 24.10. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.09. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.08. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08. | Calidi Biotherapeutics closes $6.9 million public offering | 2 | Investing.com | ||
| 22.08. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option | 2 | GlobeNewswire (USA) | ||
| 20.08. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering | 3 | GlobeNewswire (USA) | ||
| 15.08. | Calidi files to sell 1.2M common stock units | 1 | Seeking Alpha | ||
| 15.08. | Calidi Biotherapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 14.08. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.08. | Calidi Biotherapeutics GAAP EPS of -$1.99 | 1 | Seeking Alpha | ||
| 08.08. | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.08. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights | 284 | GlobeNewswire (Europe) | Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,60 | +0,13 % | Erfreuliche Studiendaten verleihen der BioNTech-Aktie wieder Rückenwind, doch für einen Durchbruch reicht es noch nicht | Vor fünf Jahren dominierte die Aktie von BioNTech noch das Börsengeschehen, mittlerweile schafft das Papier es aber nur noch selten auf das Radar der Anleger. Das Geschäft mit Corona-Impfstoffen ist... ► Artikel lesen | |
| MODERNA | 25,415 | -0,10 % | Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE | mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the... ► Artikel lesen | |
| OCUGEN | 1,283 | +2,15 % | Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit | ||
| VIKING THERAPEUTICS | 30,460 | +0,21 % | 1 Bold Prediction for Viking Therapeutics in 2026 | ||
| ABCELLERA BIOLOGICS | 2,983 | +1,43 % | AbCellera Biologics wechselt Wirtschaftsprüfer: Ernst & Young folgt auf KPMG ab 2026 | ||
| ADAPTIMMUNE THERAPEUTICS | 0,028 | -44,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 5,150 | 0,00 % | Sagimet Biosciences Inc.: Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration | SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic... ► Artikel lesen | |
| QIAGEN | 37,990 | -0,90 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| NURIX THERAPEUTICS | 18,840 | -0,89 % | Cathie Wood's ARK sells Iridium stock, buys Nurix on Wednesday | ||
| EDGEWISE THERAPEUTICS | 22,770 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 61,74 | -4,72 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,280 | -1,89 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 71,98 | +0,17 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| IMMUNOME | 23,460 | 0,00 % | Immunome prices public offering of common stock at $21.50 per share | ||
| OLEMA PHARMACEUTICALS | 34,250 | -4,41 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright |
CALIDI BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,50 % bei einem Aktienkurs von 1,310 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALIDI BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.